The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen
Abstract
BACKGROUND: Hyperglycemia, which is not uncommon during the treatment of acute lymphocytic leukemia (ALL), has been shown to be an independent predictor of adverse outcomes among hospitalized patients with undiagnosed diabetes; it also may have the potential to affect leukemic cell proliferation through altered metabolism. The purpose of the current study was to determine the prevalence of hyperglycemia during induction chemotherapy for ALL using a regimen comprised of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD) and to determine its effect on survival, duration of disease remission, and treatment‐related complications. METHODS: Two hundred seventy‐eight adult patients with previously untreated ALL who achieved a complete remission with the hyper‐CVAD regimen were evaluated. Hyperglycemia was defined as ≥ 2 glucose determinations of ≥ 200 mg/dL during the first 30 days of induction chemotherapy. Induction chemotherapy was comprised of fractionated cyclophosphamide at a dose of 300 mg/m 2 twice daily on Days 1–3, doxorubicin at a dose of 50 mg/m 2 on Day 4, vincristine at a dose of 2 mg on Days 4 and 11, and dexamethasone at a dose of 40 mg on Days 1–4 and Days 11–14 (hyper‐CVAD). Hyper‐CVAD, given in odd‐number courses (Courses 1, 3, 5, and 7), was alternated with methotrexate and cytarabine (MTX/Ara‐C), given in even‐number courses (Courses 2, 4, 6, and 8). MTX/Ara‐C was comprised of MTX at a dose of 200 mg/m 2 over 2 hours followed by 800 mg/m 2 over 22 hours on Day 1, Ara‐C at a dose of 3 g/m 2 every 12 hours for 4 doses over 2 days (Days 2 and 3), and intravenous methylprednisolone given at a dose of 50 mg twice daily on Days 1–3. The complete remission duration (CRD), survival, and treatment‐related complications were determined for patients with and without hyperglycemia; differences between the two groups were assessed using standard statistical methods. RESULTS: Hyperglycemia was found to occur in 103 patients (37%). Patients with hyperglycemia had a shorter median CRD (24 months vs. 52 months; P = 0.001) and a shorter median survival (29 months vs. 88 months; P < 0.001); they also were more likely to develop sepsis (16.5% vs. 8.0%; P = 0.03) or any complicated infection (sepsis, pneumonia, or fungal) (38.8% vs. 25.1%; P = 0.016) compared with patients without hyperglycemia. CONCLUSIONS: Patients with hyperglycemia during induction chemotherapy for ALL with the hyper‐CVAD regimen were found to have a shorter CRD, experience a significant increase in overall mortality, and be at an increased risk for developing complicated infections. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Cited by
Targeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Glucose variability and mortality in patients with sepsis*
Ali, N. A., OʼBrien, J. M., Dungan, K., Phillips, G., Marsh, C. B., Lemeshow, S., Connors, A. F., & Preiser, J.-C. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181810378 · Cited by 432
Diabetes and pancreatic cancer
Li, D. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.20771 · Cited by 315
Metadata
- Authors
- Weiser, M. A., Cabanillas, M. E., Konopleva, M., Thomas, D. A., Pierce, S. A., Escalante, C. P., Kantarjian, H. M., & O'Brien, S. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-02-12
- Volume
- 100
- Issue
- 6
- Pages
- 1179-1185
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1971347970
- Cited by
- 204
- References
- 1
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen. https://app.cochat.ai/papers/10.1002/cncr.20071
- The paper
- Weiser, M. A., Cabanillas, M. E., Konopleva, M., Thomas, D. A., Pierce, S. A., Escalante, C. P., Kantarjian, H. M., & O'Brien, S. M. (2004). Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen. Cancer. https://doi.org/10.1002/cncr.20071
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.